Caisse de depot et placement du Quebec Purchases New Position in Incyte Corporation $INCY

Posted by George Bondi on Aug 27th, 2026

Caisse de depot et placement du Quebec purchased a new stake in shares of Incyte Corporation (NASDAQ:INCY – Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,370,503 shares of the biopharmaceutical company’s stock, valued at approximately $155,360,000.

Several other institutional investors and hedge funds have also bought and sold shares of INCY. Trails Edge Capital Partners LP bought a new position in shares of Incyte during the second quarter valued at approximately $17,570,800,000. Twin Capital Management Inc. bought a new stake in shares of Incyte in the 1st quarter worth approximately $875,000. BlackRock Inc. purchased a new stake in shares of Incyte in the 2nd quarter worth approximately $2,044,189,000. GC Wealth Management RIA LLC purchased a new stake in shares of Incyte in the 4th quarter worth approximately $1,629,000. Finally, Northwestern Mutual Wealth Management Co. increased its position in Incyte by 5,218.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 596,840 shares of the biopharmaceutical company’s stock valued at $58,950,000 after buying an additional 585,618 shares in the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Incyte Stock Performance

Shares of NASDAQ:INCY opened at $128.12 on Thursday. The firm has a market cap of $25.97 billion, a price-to-earnings ratio of 16.32, a price-to-earnings-growth ratio of 4.11 and a beta of 0.76. The business has a 50-day simple moving average of $117.87 and a two-hundred day simple moving average of $104.74. Incyte Corporation has a fifty-two week low of $81.09 and a fifty-two week high of $132.60.

Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $3.09 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.94. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The firm had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same period in the previous year, the business posted $1.57 earnings per share. The business’s revenue for the quarter was up 37.7% on a year-over-year basis. As a group, research analysts predict that Incyte Corporation will post 2.61 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on INCY. Morgan Stanley set a $119.00 price objective on Incyte in a research note on Wednesday, July 29th. Royal Bank Of Canada raised their price target on Incyte from $99.00 to $109.00 and gave the company a “sector perform” rating in a report on Wednesday, July 29th. Weiss Ratings raised Incyte from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 29th. Barclays lifted their price target on Incyte from $134.00 to $139.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen downgraded shares of Incyte from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $123.10.

Check Out Our Latest Stock Analysis on Incyte

Insider Buying and Selling

In other news, EVP Patrick A. Mayes sold 41,899 shares of the stock in a transaction on Friday, July 31st. The stock was sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the transaction, the executive vice president directly owned 61,441 shares of the company’s stock, valued at $7,339,741.86. This represents a 40.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo J. Cagnoni sold 10,801 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total value of $1,356,173.56. Following the completion of the transaction, the insider owned 183,200 shares in the company, valued at approximately $23,002,592. This trade represents a 5.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 16.20% of the company’s stock.

Incyte Company Profile

(Free Report)

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.